Your session is about to expire
← Back to Search
Unpreserved Bimatoprost for Glaucoma
Study Summary
This trial is testing whether a new glaucoma medication is as effective as the current standard medication.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many people are joining this clinical trial?
"The clinical trial is presently looking for patients to enroll, with 500 individuals needed between 2 sites. The study was initially posted on 6/22/2022 and was last updated on 7/18/2022."
Are there any unfilled openings for patients who wish to enroll in this research study?
"The study, which can be found clinicaltrials.gov, is currently looking for participants. This particular trial was originally posted on June 22nd, 2020 and was last edited on July 18th, 2020."
Has Bimatoprost Ophthalmic been cleared by the FDA?
"Bimatoprost Ophthalmic, which is currently in Phase 3 clinical trials, has demonstrated efficacy in prior studies and multiple rounds of data support its safety--giving it a score of 3."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger